



Immunotherapy of Cancer

Saturday, November 11, 2017

8:00 a.m. – 9:30 a.m.

Speakers

Katy Rezvani, MD, PhD

Ann Leen, PhD

Nirav Shah, MD, MSHP

Session Objectives

At the conclusion of this session, attendees will be able to:

1. Identify the background and development of three cancer immunotherapies.
2. Explore the differences between cancer immunotherapies.
3. Examine manufacturing of immunotherapy products.



Conflict of Interest/Financial Disclosure

The planners and speaker(s) have disclosed the following financial relationships and/or conflicts of interest:

Ann Leen, PhD	ViraCyte LLC – Equity (Co-founder); Marker Therapeutics – Equity (Co-founder)
Cynthia Vierra-Green	None
Katy Rezvani, MD, PhD	None
Nirav Shah, MD, MSHP	Kite Pharmaceuticals – Honorarium (Advisory Board); Jazz Pharmaceuticals – Honorarium (Consultant)
Ruth Bakken, RN, BSN, CHTC	None
Steve Spellman	None